- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05906992
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: SoYoung Yoo
- Phone Number: +82 32 850 5791
- Email: soyoung.yoo@celltrion.com
Study Contact Backup
- Name: JinHo Lee
- Phone Number: +82 32 850 5787
- Email: jinho.lee2@celltrion.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient diagnosed as multiple sclerosis (MS) in accordance with the revised McDonald criteria.
- Patient has evidence of recent MS activity as defined in the study protocol
- Patient has neurological stability for ≥30 days.
- Patient with 0 to 6.0 (both inclusive) on the EDSS score.
Exclusion Criteria:
- Patient diagnosed with primary or secondary progressive MS.
- Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.
- Patient unable to complete or has a contraindication to an MRI
- Patient with contraindications and/or severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or etcs defined in the study protocol.
- Patient who has currently or history of any of medical conditions described in the study protocol.
- Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CT-P53
CT-P53(Ocrelizumab)
|
Intravenous(IV) infusion
Other Names:
|
Active Comparator: US-Ocrevus
US-licensed Ocrevus(Ocrelizumab)
|
Intravenous(IV) infusion
Other Names:
|
Active Comparator: EU-Ocrevus
EU-approved Ocrevus(Ocrelizumab)
|
Intravenous(IV) infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration-time curve in PK group
Time Frame: Up to Week 24
|
To demonstrate PK comparability in terms of the area under the concentration time curve in patients with RRMS as follows:
|
Up to Week 24
|
Total number of new GdE lesions on T1-weighted brain MRI in Main study group
Time Frame: Up to Week 24
|
To demonstrate the equivalence of CT-P53 to reference drug (EU-Ocrevus and US-Ocrevus) in terms of efficacy in patients with RRMS as determined by the total number of new gadolinium-enhancing (GdE) lesions on T1-weighted brain magnetic resonance imaging (MRI)
|
Up to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absoulte CD19+ B-cell counts for PD assessments
Time Frame: Up to Week 96
|
To assess PD of CT-P53 and reference drug (EU-Ocrevus and US-Ocrevus) as follows: • Absolute CD19+ B-cell counts |
Up to Week 96
|
Area under the concentration-time curve in PK group
Time Frame: Up to Week 16
|
Area under the concentration-time curve from time zero to Week 16
|
Up to Week 16
|
Total body clearance in PK group
Time Frame: Up to Week 2
|
Total body clearance covering both administrations at Weeks 0 and 2 (CL)
|
Up to Week 2
|
Volume of distribution at steady state in PK group
Time Frame: Up to Week 2
|
Volume of distribution at steady state covering both administrations at Week 0 and 2 (Vss)
|
Up to Week 2
|
Safety: Immunogenecity
Time Frame: Up to Week 96
|
Number and percentage of patients with positive antidrug-antibody and neutralizing antibody results
|
Up to Week 96
|
Annualized Relapse Rate (ARR)
Time Frame: Up to Week 96
|
The total number of protocol-defined MS relapses for each patient will be counted and listed.
Annualized relapse rate (ARR) will be calculated by the total number of protocol-defined relapses for all patients divided by time-in-study by patient.
|
Up to Week 96
|
Change in Expanded Disability Status Score (EDSS)
Time Frame: Up to Week 96
|
The EDSS score will be listed and descriptive statistics for actual value and change in EDSS score from baseline to Weeks 24, 48 and 96 will be summarized by treatment group and visit. An increase ≥1.5 point from baseline EDSS score is defined as disability progression. A reduction ≥1.0 point from baseline EDSS score is defined as disability improvement. |
Up to Week 96
|
Change in Multiple Sclerosis Functional Composite Score (MSFCS)
Time Frame: Up to Week 96
|
There are three components to the MSFCS; (1) the average scores of two trials of T25-FW (2) the average scores on the 9-HPT (the two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged) (3) the number of correct answers from the PASAT-3.
Multiple Sclerosis Functional Composite Score (MSFCS) is based on the concept that scores for these three dimensions (arm, leg, and cognitive functions) are combined to create a single score (the MSFCS) that can be used to detect change over time in MS patients
|
Up to Week 96
|
Total Number of Lesions on Brain Magnetic Resonance Imaging
Time Frame: Up to Week 96
|
The total number of lesions on brain MRI will be calculated as the cumulative sum of the individual number of the lesions at each scheduled visit
|
Up to Week 96
|
Volume of Hypointense Lesions on T1-weighted Brain Magnetic Resonance Imaging
Time Frame: Up to Week 96
|
Actual value of volume of hypointense lesions on T1-weighted brain MRI will be listed by treatment group and visit.
Descriptive statistics for actual value and change in volume of hypointense lesions on T1-weighted brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group
|
Up to Week 96
|
Brain Volume on Brain Magnetic Resonance Imaging
Time Frame: Up to Week 96
|
Change in brain volume is defined as the brain volume at pre-specified time point minus brain volume at baseline.
Actual value of brain volume on brain MRI will be listed by treatment group.
Descriptive statistics for actual value and percentage change in brain volume on brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group.
|
Up to Week 96
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: Up to Week 96
|
All reported terms of AEs will be coded to system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) and severity grading of AEs will be recorded according to the CTCAE Version 5.0
|
Up to Week 96
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: MinJi Ma, Celltrion, Inc.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Immunologic Factors
- Ocrelizumab
Other Study ID Numbers
- CT-P53 3.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing-remitting Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on CT-P53
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Oral and Maxillofacial Malignant TumorsChina
-
Shenzhen SiBiono GeneTech Co.,LtdUnknown
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Affiliated Hospital of Jiangnan UniversityCompleted
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownHCC | DiabetesChina
-
National Cancer Institute (NCI)WithdrawnSarcoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Colon CancerUnited States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Hepatocellular Carcinoma (HCC)China
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI)CompletedOvarian Cancer | Peritoneal Cavity CancerUnited States